Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 7/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5965372 | 0.79 | PIK3CA (0.44) | TSHRPIK3CAPIK3CDPIK3CBPIK3R1 | |
| SCHEMBL1593535 | 0.77 | MAPK1 (0.47) | TSHRPIK3CAPIK3CDPIK3CBPIK3R1 | |
| SCHEMBL1594484 | 0.75 | NPY5R (0.45) | MEN1ALDH1A1KMT2AADRA2ANPY5R | |
| SCHEMBL3918722 | 0.71 | ALDH1A1 (0.45) | HTTKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL1594423 | 0.70 | NPY5R (0.54) | PIK3CAPIK3CDPIK3CBPIK3R1MEN1 | |
| SCHEMBL14301519 | 0.68 | ADAMTS5 (0.38) | TSHRPIK3CAPIK3CDPIK3CBPIK3R1 | |
| SCHEMBL1593463 | 0.68 | NPY5R (0.43) | ADRA2ANPY5RCA1CA2CA9 | |
| SCHEMBL8885835 | 0.68 | TSHR (0.69) | TSHRPIK3CAPIK3CDPIK3CBHTT | |
| SCHEMBL15840099 | 0.68 | TSHR (0.54) | TSHRPIK3CAPIK3CDPIK3CBHTT | |
| SCHEMBL6238836 | 0.68 | KDM4E (0.58) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919329-B2 | Using proopiomelanocortin neuronal regulatory sequences to identify agents that affects caloric intake, energy expenditure, appetite or food intake; treating eating disorders and/or cachexia | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2011-04-05 | — | — | US | disclosed |
| EP-2050460-A1 | PYY and agonists thereof for modification of feeding behaviour | Imperial Innovations Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| US-7459432-B2 | Modification of feeding behavior | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 2008-12-02 | — | — | US | disclosed |
| US-20080213803-A1 | ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR | OREGON HEALTH & SCIENCE UNIVERSITY | 2008-09-04 | — | — | US | disclosed |
| US-20080045524-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2008-02-21 | — | — | US | disclosed |
| US-20080045524-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2008-02-21 | — | — | US | disclosed |
| EP-1816127-A1 | TRIAZINE DERIVATIVES FOR USE AS SELECTIVE NPY (Y5) ANTAGONISTS | H. Lundbeck A/S (DK) | 2007-08-08 | — | — | EP | disclosed |
| US-7189720-B2 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2007-03-13 | — | — | US | disclosed |
| US-7189720-B2 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2007-03-13 | — | — | US | disclosed |
| EP-1585956-A2 | ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR | Oregon Health and Science University (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| EP-1499277-A2 | MODIFICATION OF FEEDING BEHAVIOR | Imperial College Innovations Limited (GB) | 2005-01-26 | — | — | EP | disclosed |
| US-20050015820-A1 | Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-01-20 | — | — | US | disclosed |
| WO-2003026591-A9 | MODIFICATION OF FEEDING BEHAVIOR | IMP COLLEGE INNOVATIONS LTD (GB) | 2004-07-08 | — | — | WO | disclosed |
| US-20040019050-A1 | Selective NPY (Y5) antagonists (triazines) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-01-29 | — | — | US | disclosed |
| US-6569856-B2 | Treatment of feeding disorders, obesity, bulimia nervosa, sexual/reproductive disorders, depression, epileptic seizure, cardiovascular disorders, sleep disturbances | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-05-27 | — | — | US | disclosed |
| WO-2003027637-A2 | ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR | OREGON HEALTH AND SCIENCE UNIVERSITY (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003026591-A2 | MODIFICATION OF FEEDING BEHAVIOR | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 2003-04-03 | — | — | WO | disclosed |
| US-20020103201-A1 | Selective NPY (Y5) antagonists (triazines) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-01 | — | — | US | disclosed |
| US-6340683-B1 | NEUROPEPTIDE Y ANTAGONISTS; TREATING EATING DISORDERS, SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION, EPILEPTIC SEIZURE, HYPERTENSION, CEREBRAL HEMORRHAGE, CONGESTIVE HEART FAILURE, SLEEP DISTURBANCES | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019050-A1 | Selective NPY (Y5) antagonists (triazines) | NPY5R, NPY1R, NPY2R | TSHR 126/4885PIK3CA 2991/4885PIK3CD 2385/4885 |
| US-20080045524-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | TSHR 142/4885PIK3CA 2272/4885PIK3CD 1607/4885 |
| US-20020103201-A1 | Selective NPY (Y5) antagonists (triazines) | NPY5R, NPY1R, NPY2R | TSHR 126/4885PIK3CA 2991/4885PIK3CD 2385/4885 |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | TSHR 142/4885PIK3CA 2272/4885PIK3CD 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.